

**ELECTION AND REMARK**

Applicant hereby elects the invention of Group 1 corresponding to **Claim 1-23 and 26-31** for continued prosecution at this time. Applicants' election is with traverse as to Groups 2-3 for the following reasons:

Group 2 – **Claim 24** relates to a process for preparing citalopram, followed by subjecting the crude mixture of citalopram to the purification process according to claim 1.

Group 3 – **Claim 25** relates to a process for preparing citalopram, followed by subjecting the crude mixture of citalopram to the purification process according to claim 1.

**Claims 24 and 25** therefore include all the features of claim 1, (in the elected Group 1 invention) which was found to be patentable by the PCT examiner.

As the groups 2 and 3 are combinations with the specific process steps of the Group 1 (e.g. claim 1) invention, no restriction can be sustained as between a combination including the specific subcombination. See MPEP 806.05(c). I.

Restriction Requirement  
U.S. Patent Application No. 10/565,736

Group Unit No.: 1625

Therefore, reconsideration and modification of the restriction to include **Claims 1-25 and 26-31** within the election invention is requested.

Respectfully submitted,



Thomas P. Pavelko  
Registration No.: 31,689

TPP/mvj  
Attorney Docket No.: TPP31792

NOVAK DRUCE + QUIGG LLP  
1300 Eye Street, N.W.  
Suite 1000, West Tower  
Washington, D.C. 20005  
Telephone No.: 202.659.0100  
Facsimile No.: 202.659.0105

Date: February 19, 2008